NCT01691547 - A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 17, 2012

Primary Completion Date

March 8, 2013

Study Completion Date

March 8, 2013

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UMEC /VI

Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.

DRUG

UMEC

Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.

DRUG

Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.

DRUG

Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore